Century Therapeutics reports Q3 2026 results, two lead programs on track for clinic
Century said CNTY-813 remains set for an IND filing in the fourth quarter of 2026 and CNTY-308 is still expected to enter the clinic this year, with cash extending into early 2029.
Century Therapeutics reported third quarter 2026 results on November 12, 2026, with updates on its two lead cell therapy programs. The company said it expects to submit an IND for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, in the fourth quarter of 2026.1 Following a pre-IND meeting, Century and the FDA reached general alignment on the nonclinical data package, the Phase 1 manufacturing process, and the proposed Phase 1/2 clinical trial design.1 Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated in the second half of 2027.1
At the EASD 2026 meeting, Century presented nonclinical data showing that islets edited with its Allo-Evasion 5.0 technology restored normal blood sugar levels in streptozotocin-induced diabetic mice and sustained that control until the graft was removed, in a study that ran for more than eleven months.1 The company also reported that mice given clinical-scale islets that had undergone 96 hours of cold storage reached normal glucose levels within 30 days and held that control through three months of follow-up, supporting the planned clinical supply chain approach.1
For CNTY-308, a CD19-targeted CAR-iT therapy, Century said it aligned with health authorities on nonclinical, manufacturing, and Phase 1 parameters, and the program is anticipated to enter the clinic in 2026.1
On financing, cash, cash equivalents, and investments were $174.1 million as of September 30, 2026, compared with $117.1 million as of December 31, 2025.1 The company estimates this cash position will support operations into the first quarter of 2029.1 Separately, Century announced the appointment of Joseph Truitt to its Board of Directors.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.